Multinomial phase II trial designs [1]

Journal of Clinical Oncology

Volumn 20, Issue 2, 2002, Pages 599-

  Freidlin, Boris ^a   Dancey, Janet ^a   Korn, Edward L ^a   Zee, Benny ^a   Eisenhauer, Elizabeth ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; CYTOSTASIS; CYTOTOXICITY; DOSE RESPONSE; DRUG DESIGN; HUMAN; LETTER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCREENING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; DECISION MAKING; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; STATISTICS;

EID: 0037080284     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Application of a new multinomial phase II stopping rule using response and early progression
2. Multinomial phase II cancer trials incorporating response and early progression